Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated...
BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin,...
BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue...
The law firm of Kirby McInerney LLP continues its investigation on behalf of Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK) investors concerning the Company’s...
Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive Officer Cheryl Blanchard to Become Executive Chair of the Board of Directors...
The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Anika Therapeutics, Inc. (“Anika” or the “Company”) (NASDAQ:ANIK) investors concerning the Company’s...
Commercial Channel revenue up 22% with continued strong Integrity ™ Implant System and Hyalofast ® growth, and double-digit International OA Pain Management growth Third and final Hyalofast...
BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final...